Get started
RRR

CYBIN INC

No trades
See on Supercharts
Overview
Financials Discussions Forecast

R7E chart


Full chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪153.64 M‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.91EUR
Net income (FY)
‪−53.42 M‬EUR
Revenue (FY)
0.00EUR
Shares float
—
Beta (1Y)
—

About CYBIN INC


Sector
Health Technology
CEO
Douglas L. Drysdale
Headquarters
Toronto
Website
cybin.com
Founded
2016
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CYBIN INC stocks are traded under the ticker R7E.
R7E stock has risen by 1.25% compared to the previous week, the month change is a 1.25% rise, over the last year CYBIN INC has showed a 1.25% increase.
We've gathered analysts' opinions on CYBIN INC future price: according to them, R7E price has a max estimate of 5.51 EUR and a min estimate of 1.00 EUR. Watch R7E chart and read a more detailed CYBIN INC stock forecast: see what analysts think of CYBIN INC and suggest that you do with its stocks.
Yes, you can track CYBIN INC financials in yearly and quarterly reports right on TradingView.
CYBIN INC is going to release the next earnings report on Nov 13, 2024. Keep track of upcoming events with our Earnings Calendar.
R7E earnings for the last quarter are −0.01 EUR per share, whereas the estimation was −0.03 EUR resulting in a 53.85% surprise. The estimated earnings for the next quarter are −0.02 EUR per share. See more details about CYBIN INC earnings.
CYBIN INC revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
R7E net income for the last quarter is ‪−10.11 M‬ EUR, while the quarter before that showed ‪−14.60 M‬ EUR of net income which accounts for 30.75% change. Track more CYBIN INC financial stats to get the full picture.
No, R7E doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, R7E shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYBIN INC stock right from TradingView charts — choose your broker and connect to your account.